Phase 1b trial for long-acting malaria injectable begins in Rwanda

Medicines for Malaria Venture and Rinda Ubuzima have launched the first Phase 1 trial of a malaria long-acting injectable to be conducted in Africa.

Phase 1b trial for long-acting malaria injectable begins in Rwanda
Photo: The Sun Nigeria

Medicines for Malaria Venture (MMV) and Rinda Ubuzima have launched a Phase 1b clinical trial for a potential long-acting injectable (LAI) for malaria prevention. This study is the first Phase 1 trial of a malaria LAI to be conducted in Africa. The trial focuses on a compound known as MMV371.

The Phase 1b study will evaluate the safety and tolerability of MMV371 in Rwandan adults and adolescents. Researchers will also explore its efficacy and how the body absorbs and processes the compound. This follows earlier clinical research in the United Kingdom, which found the compound was well tolerated in healthy adults and showed potential to provide protection for approximately 3 months.

“To eliminate malaria, we will need not only wider access to today’s tools but also the next generation of prevention technologies,” said Dr Martin Fitchet, Chief Executive Officer of MMV. Dr Fitchet said long-acting injectables have the potential to redefine how malaria prevention is delivered by providing sustained protection from a single administration.

Marie Michele Umulisa, Executive Director of Rinda Ubuzima, said conducting the study in Rwanda demonstrates that partnerships are essential to ensuring African researchers and institutions are active contributors to developing solutions for the communities that need them most. The collaboration reflects a shared commitment to advancing innovation through locally led research.

Malaria remains a major public health challenge, with the World Health Organization reporting over 280 million cases and 600,000 deaths in 2024. Approximately 95 percent of these cases and deaths occurred in Africa. The emergence of antimalarial drug resistance and changing disease patterns driven by climate change-related extreme weather events highlight the need for continued innovation.

Key facts

  • MMV and Rinda Ubuzima launched a Phase 1b clinical trial for the malaria prevention compound MMV371 in Rwanda.
  • The trial is the first Phase 1 trial of a malaria long-acting injectable to be conducted in Africa.
  • In 2024, malaria caused over 280 million cases and 600,000 deaths, with 95 percent occurring in Africa.

Three perspectives

Neutral

Medicines for Malaria Venture and Rinda Ubuzima have launched a Phase 1b clinical trial for a potential long-acting injectable for malaria prevention in Rwanda.

Positive

The trial represents a step toward providing sustained protection from a single administration and strengthening locally led scientific innovation in Africa.

Negative

The disease remains a major challenge, with 95 percent of the 600,000 malaria deaths in 2024 occurring in Africa.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Grand Theft Auto VI launches worldwide after 13-year wait
Next storyGrand Theft Auto VI launches worldwide after 13-year wait

All sections

Edition